|

FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases

RECRUITINGSponsored by Assistance Publique - Hôpitaux de Paris
Actively Recruiting
SponsorAssistance Publique - Hôpitaux de Paris
Started2026-05-01
Est. completion2030-11-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07467434

Summary

SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult subjects aged 18 years and older
* Adenocarcinoma of the middle and/or lower rectum pMMR T3, T4, and/or N+
* Resectable synchronous liver metastases

Exclusion Criteria:

* Minor under the age of 18.
* Presence of extrahepatic metastases
* Induction chemotherapy with FOLFIRINOX of less than 2 courses

Conditions7

Antineoplastic Combined Chemotherapy ProtocolsCancerLiver CancerLiver DiseaseRectal CancerSurgical TherapySynchronous Liver Metastases

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.